Botulinum toxin has been used to treat persistent erythema and flushing in rosacea for several years. A recent study added further value and reported that botulinum toxin improves mild-to-moderate acne vulgaris and erythematotelangiectatic rosacea. The study findings were published in the Journal of Cosmetic Dermatology on March 21, 2022.
There are several treatments for the management of rosacea, stratified according to the predominant lesions and their severity. However, the response of erythematotelangiectatic rosacea to conventional treatment is currently unsatisfactory. The application of intradermal botulinum toxin is an alternative treatment for refractory erythema and flushing. This intervention has demonstrated more prolonged effects without a rebound effect.

Botulin toxin (BTX) is a potent neurotoxin produced by the bacterium Clostridium botulinum, since its approval by FDA in 2002 for the cosmetic purpose has been widely used. Previous studies have shown that botox exerts its activity on various types of skin cells and can be used in some dermatological diseases. To further explore its effect, Dr Lucia Calvisi MD and her team conducted a study to demonstrate how to use a peculiar dilution of botulinum toxin type A in the treatment of some dermatological diseases like mild-to-moderate acne vulgaris and erythematotelangiectatic rosacea.
In this present study, the researchers included 50 patients among which 35 patients had mild-to-moderate acne, and 15 patients had erythematotelangiectatic rosacea. The researchers treated both groups of patients with a specific dilution of onabotulinum toxin A called Microbotox. They further assessed patients' images which were before and 4 weeks after the treatment.
Upon evaluation, both the researchers and the patients were extremely satisfied with their treatments. The researchers reported that there was no immediate or delayed complication in none of both groups of patients.
They wrote, "Botulinum toxin shows a great promise either in dermatological disease like mild-to-moderate acne vulgaris and erythematotelangiectatic rosacea. Microbotox appears to be a valid, long-lasting, and a standardized approach to treat these kind of two disease."
For further information:
DOI: https://doi.org/10.1111/jocd.14692
Keywords: Botulin toxin, Botox, BTX, acne vulgaris, erythematotelangiectatic rosacea, Microbotox, Onabotulinum toxin A, dermatological disease
Journal of Cosmetic Dermatology.